Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Bringing genetic testing to the hospital lab.

Hawkins MJ.

Health Manag Technol. 2017 Apr;38(4):24. No abstract available.

PMID:
29474045
2.

Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia.

Cornely OA, Leguay T, Maertens J, Vehreschild MJGT, Anagnostopoulos A, Castagnola C, Verga L, Rieger C, Kondakci M, Härter G, Duarte RF, Allione B, Cordonnier C, Heussel CP, Morrissey CO, Agrawal SG, Donnelly JP, Bresnik M, Hawkins MJ, Garner W, Gökbuget N; AmBiGuard Study Group.

J Antimicrob Chemother. 2017 Aug 1;72(8):2359-2367. doi: 10.1093/jac/dkx133.

PMID:
28575414
3.

Expectations for Treatment in Pediatric Weight Management and Relationship to Attrition.

Rhodes ET, Boles RE, Chin K, Christison A, Testa EG, Guion K, Hawkins MJ, Petty CR, Sallinen Gaffka B, Santos M, Shaffer L, Tucker J, Hampl SE.

Child Obes. 2017 Apr;13(2):120-127. doi: 10.1089/chi.2016.0215. Epub 2017 Jan 16.

4.

Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.

Barr PM, Saylors GB, Spurgeon SE, Cheson BD, Greenwald DR, O'Brien SM, Liem AK, Mclntyre RE, Joshi A, Abella-Dominicis E, Hawkins MJ, Reddy A, Di Paolo J, Lee H, He J, Hu J, Dreiling LK, Friedberg JW.

Blood. 2016 May 19;127(20):2411-5. doi: 10.1182/blood-2015-12-683516. Epub 2016 Mar 11.

5.

Managing juvenile idiopathic arthritis-associated uveitis.

Hawkins MJ, Dick AD, Lee RJ, Ramanan AV, Carreño E, Guly CM, Ross AH.

Surv Ophthalmol. 2016 Mar-Apr;61(2):197-210. doi: 10.1016/j.survophthal.2015.10.005. Epub 2015 Oct 24. Review.

PMID:
26599495
6.

Biomechanical comparison of traditional anchors to all-suture anchors in a double-row rotator cuff repair cadaver model.

Goschka AM, Hafer JS, Reynolds KA, Aberle NS 2nd, Baldini TH, Hawkins MJ, McCarty EC.

Clin Biomech (Bristol, Avon). 2015 Oct;30(8):808-13. doi: 10.1016/j.clinbiomech.2015.06.009. Epub 2015 Jun 14.

PMID:
26117162
7.

Parent perspectives on attrition from tertiary care pediatric weight management programs.

Hampl S, Demeule M, Eneli I, Frank M, Hawkins MJ, Kirk S, Morris P, Sallinen BJ, Santos M, Ward WL, Rhodes E.

Clin Pediatr (Phila). 2013 Jun;52(6):513-9. doi: 10.1177/0009922813482515. Epub 2013 Mar 28. Erratum in: Clin Pediatr (Phila). 2014 Mar;53(3):NP1.

PMID:
23539682
8.

Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma.

Vail DM, Thamm DH, Reiser H, Ray AS, Wolfgang GH, Watkins WJ, Babusis D, Henne IN, Hawkins MJ, Kurzman ID, Jeraj R, Vanderhoek M, Plaza S, Anderson C, Wessel MA, Robat C, Lawrence J, Tumas DB.

Clin Cancer Res. 2009 May 15;15(10):3503-10. doi: 10.1158/1078-0432.CCR-08-3113. Epub 2009 May 5.

9.

Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel.

Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N, Hawkins MJ, Sparreboom A, Figg WD.

Clin Cancer Res. 2008 Jul 1;14(13):4200-5. doi: 10.1158/1078-0432.CCR-07-4592.

10.

Protein nanoparticles as drug carriers in clinical medicine.

Hawkins MJ, Soon-Shiong P, Desai N.

Adv Drug Deliv Rev. 2008 May 22;60(8):876-85. doi: 10.1016/j.addr.2007.08.044. Epub 2008 Feb 7. Review.

PMID:
18423779
11.

Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.

Rizvi NA, Riely GJ, Azzoli CG, Miller VA, Ng KK, Fiore J, Chia G, Brower M, Heelan R, Hawkins MJ, Kris MG.

J Clin Oncol. 2008 Feb 1;26(4):639-43. doi: 10.1200/JCO.2007.10.8605.

PMID:
18235124
12.

Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase.

Greco MN, Hawkins MJ, Powell ET, Almond HR Jr, de Garavilla L, Hall J, Minor LK, Wang Y, Corcoran TW, Di Cera E, Cantwell AM, Savvides SN, Damiano BP, Maryanoff BE.

J Med Chem. 2007 Apr 19;50(8):1727-30. Epub 2007 Mar 16.

PMID:
17361995
13.

Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors.

Stinchcombe TE, Socinski MA, Walko CM, O'Neil BH, Collichio FA, Ivanova A, Mu H, Hawkins MJ, Goldberg RM, Lindley C, Dees EC.

Cancer Chemother Pharmacol. 2007 Oct;60(5):759-66. Epub 2007 Feb 7.

14.

Facile dephosphonylation of beta-ketophosphonic acids: mechanistic studies.

Hawkins MJ, Powell ET, Leo GC, Gauthier DA, Greco MN, Maryanoff B.

Org Lett. 2006 Aug 3;8(16):3429-31.

PMID:
16869627
15.

Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer.

Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, Bhar P, Hawkins MJ.

Ann Oncol. 2006 Aug;17(8):1263-8. Epub 2006 Jun 1.

PMID:
16740598
16.

Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.

Nyman DW, Campbell KJ, Hersh E, Long K, Richardson K, Trieu V, Desai N, Hawkins MJ, Von Hoff DD.

J Clin Oncol. 2005 Nov 1;23(31):7785-93.

PMID:
16258082
17.

A new family of Fisher-curves estimates Fisher's alpha more accurately.

Schulte RP, Lantinga EA, Hawkins MJ.

J Theor Biol. 2005 Feb 7;232(3):305-13.

PMID:
15572056
18.

Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor.

Marshall JL, Kindler H, Deeken J, Bhargava P, Vogelzang NJ, Rizvi N, Luhtala T, Boylan S, Dordal M, Robertson P, Hawkins MJ, Ratain MJ.

Invest New Drugs. 2005 Jan;23(1):31-7.

PMID:
15528978
19.

Placebo-controlled trial of bexarotene, a retinoid x receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancer.

Rizvi N, Hawkins MJ, Eisenberg PD, Yocum RC, Reich SD; Ligand L1069-20 Working Group.

Clin Lung Cancer. 2001 Feb;2(3):210-5.

PMID:
14700480
20.

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

Marshall JL, Rizvi N, Kauh J, Dahut W, Figuera M, Kang MH, Figg WD, Wainer I, Chaissang C, Li MZ, Hawkins MJ.

J Exp Ther Oncol. 2002 Nov-Dec;2(6):325-32.

PMID:
12440223
21.

Phase I study of prolonged infusion Bryostatin-1 in patients with advanced malignancies.

Marshall JL, Bangalore N, El-Ashry D, Fuxman Y, Johnson M, Norris B, Oberst M, Ness E, Wojtowicz-Praga S, Bhargava P, Rizvi N, Baidas S, Hawkins MJ.

Cancer Biol Ther. 2002 Jul-Aug;1(4):409-16.

PMID:
12432257
22.

Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer.

Rizvi NA, Marshall JL, Ness E, Hawkins MJ, Kessler C, Jacobs H, Brenckman WD Jr, Lee JS, Petros W, Hong WK, Kurie JM.

J Clin Oncol. 2002 Aug 15;20(16):3522-32.

PMID:
12177113
23.

Nonpeptide inhibitors of cathepsin G: optimization of a novel beta-ketophosphonic acid lead by structure-based drug design.

Greco MN, Hawkins MJ, Powell ET, Almond HR Jr, Corcoran TW, de Garavilla L, Kauffman JA, Recacha R, Chattopadhyay D, Andrade-Gordon P, Maryanoff BE.

J Am Chem Soc. 2002 Apr 17;124(15):3810-1.

PMID:
11942800
24.

A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers.

Bhargava P, Marshall JL, Dahut W, Rizvi N, Trocky N, Williams JI, Hait H, Song S, Holroyd KJ, Hawkins MJ.

Clin Cancer Res. 2001 Dec;7(12):3912-9.

25.

Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer.

Bhargava P, Marshall JL, Fried K, Williams M, Lefebvre P, Dahut W, Hanfelt J, Gehan E, Figuera M, Hawkins MJ, Rizvi NA.

Cancer Chemother Pharmacol. 2001 Aug;48(2):95-103.

PMID:
11561784
26.

Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin's lymphoma treated with interferon alfa (IFN-alpha2a) plus an anthracycline-based induction regimen.

Smalley RV, Weller E, Hawkins MJ, Oken MM, O'Connell MJ, Haase-Statz S, Borden EC.

Leukemia. 2001 Jul;15(7):1118-22.

PMID:
11455982
27.

Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin.

Peck RA, Hewett J, Harding MW, Wang YM, Chaturvedi PR, Bhatnagar A, Ziessman H, Atkins F, Hawkins MJ.

J Clin Oncol. 2001 Jun 15;19(12):3130-41.

PMID:
11408511
28.

Risk factors for clinical salmonellosis in Virginia, USA cattle herds.

Warnick LD, Crofton LM, Pelzer KD, Hawkins MJ.

Prev Vet Med. 2001 May 1;49(3-4):259-75.

PMID:
11311958
29.

Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: case report and review of the literature.

Bangalore N, Bhargava P, Hawkins MJ, Bhargava P.

Ann Oncol. 2001 Feb;12(2):271-4. Review.

PMID:
11300337
30.

Phase II evaluation of thalidomide in patients with metastatic breast cancer.

Baidas SM, Winer EP, Fleming GF, Harris L, Pluda JM, Crawford JG, Yamauchi H, Isaacs C, Hanfelt J, Tefft M, Flockhart D, Johnson MD, Hawkins MJ, Lippman ME, Hayes DF.

J Clin Oncol. 2000 Jul;18(14):2710-7.

PMID:
10894870
31.

A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.

Chen HX, Marshall JL, Ness E, Martin RR, Dvorchik B, Rizvi N, Marquis J, McKinlay M, Dahut W, Hawkins MJ.

Clin Cancer Res. 2000 Apr;6(4):1259-66.

32.

Docetaxel and gemcitabine combinations in non-small cell lung cancer.

Rizvi NA, Spiridonidis CH, Davis TH, Bhargava P, Marshall JL, Dahut W, Figuera M, Hawkins MJ.

Semin Oncol. 1999 Oct;26(5 Suppl 16):27-31; discussion 41-2. Review.

PMID:
10585006
33.

Depressive symptomatology and specificity of social support.

Hawkins WE, Tan PP, Hawkins MJ, Smith E, Ryan E.

Psychol Rep. 1999 Jun;84(3 Pt 2):1180-6.

PMID:
10477937
34.

A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer.

Bhargava P, Marshall JL, Rizvi N, Dahut W, Yoe J, Figuera M, Phipps K, Ong VS, Kato A, Hawkins MJ.

Clin Cancer Res. 1999 Aug;5(8):1989-95.

35.

Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen.

Marshall JL, Hawkins MJ, Tsang KY, Richmond E, Pedicano JE, Zhu MZ, Schlom J.

J Clin Oncol. 1999 Jan;17(1):332-7.

PMID:
10458251
36.

A Phase I study of LGD1069 in adults with advanced cancer.

Rizvi NA, Marshall JL, Dahut W, Ness E, Truglia JA, Loewen G, Gill GM, Ulm EH, Geiser R, Jaunakais D, Hawkins MJ.

Clin Cancer Res. 1999 Jul;5(7):1658-64.

37.

A pilot trial of GM-CSF and MDX-H210 in patients with erbB-2-positive advanced malignancies.

Posey JA, Raspet R, Verma U, Deo YM, Keller T, Marshall JL, Hodgson J, Mazumder A, Hawkins MJ.

J Immunother. 1999 Jul;22(4):371-9.

PMID:
10404439
38.

Heterocycle-peptide hybrid compounds. Aminotriazole-containing agonists of the thrombin receptor (PAR-1).

McComsey DF, Hawkins MJ, Andrade-Gordon P, Addo MF, Oksenberg D, Maryanoff BE.

Bioorg Med Chem Lett. 1999 May 17;9(10):1423-8.

PMID:
10360749
39.

Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer.

Marshall JL, Wellstein A, Rae J, DeLap RJ, Phipps K, Hanfelt J, Yunmbam MK, Sun JX, Duchin KL, Hawkins MJ.

Clin Cancer Res. 1997 Dec;3(12 Pt 1):2347-54.

40.

Phase I study of 9-cis-retinoic acid (ALRT1057 capsules) in adults with advanced cancer.

Rizvi NA, Marshall JL, Ness E, Yoe J, Gill GM, Truglia JA, Loewen GR, Jaunakais D, Ulm EH, Hawkins MJ.

Clin Cancer Res. 1998 Jun;4(6):1437-42.

41.

Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer.

Wojtowicz-Praga S, Torri J, Johnson M, Steen V, Marshall J, Ness E, Dickson R, Sale M, Rasmussen HS, Chiodo TA, Hawkins MJ.

J Clin Oncol. 1998 Jun;16(6):2150-6.

PMID:
9626215
42.

Depressive symptoms and HIV-risk behavior in inner-city users of drug injections.

Hawkins WE, Latkin C, Hawkins MJ, Chowdury D.

Psychol Rep. 1998 Feb;82(1):137-8.

PMID:
9520544
43.

Fatigue: definitions, mechanisms, and paradigms for study.

Dalakas MC, Mock V, Hawkins MJ.

Semin Oncol. 1998 Feb;25(1 Suppl 1):48-53. Review.

PMID:
9482540
44.

Matrix metalloproteinase inhibitors.

Wojtowicz-Praga SM, Dickson RB, Hawkins MJ.

Invest New Drugs. 1997;15(1):61-75. Review.

PMID:
9195290
45.

Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer.

Wojtowicz-Praga S, Low J, Marshall J, Ness E, Dickson R, Barter J, Sale M, McCann P, Moore J, Cole A, Hawkins MJ.

Invest New Drugs. 1996;14(2):193-202.

PMID:
8913840
46.

The clinical experience with antiangiogenic agents.

Marshall JL, Hawkins MJ.

Breast Cancer Res Treat. 1995;36(2):253-61. Review.

PMID:
8534872
47.

Clinical trials of antiangiogenic agents.

Hawkins MJ.

Curr Opin Oncol. 1995 Jan;7(1):90-3. Review.

PMID:
7535103
48.

Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors.

Sparano JA, Fisher RI, Weiss GR, Margolin K, Aronson FR, Hawkins MJ, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH, et al.

J Immunother Emphasis Tumor Immunol. 1994 Oct;16(3):216-23.

PMID:
7834121
49.

A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinoma.

Hawkins MJ, Atkins MB, Dutcher JP, Fisher RI, Weiss GR, Margolin KA, Rayner AA, Sznol M, Parkinson DR, Paietta E, et al.

J Immunother Emphasis Tumor Immunol. 1994 Jan;15(1):74-8.

PMID:
8110733
50.

Interleukin-2 antitumor and effector cell responses.

Hawkins MJ.

Semin Oncol. 1993 Dec;20(6 Suppl 9):52-9. Review.

PMID:
8284693

Supplemental Content

Loading ...
Support Center